Cipla gets USFDA nod for cancer drug
Cipla's Lenalidomide capsules are therapeutic equivalent generic version of Bristol Myers Squibb's Revlimid capsules Drug firm Cipla on Wednesday said it has received approval from the US health regulator for Lenalidomide capsule, a drug used to treat various types of cancer. The company has received the final approval from the US Food and Drug Administration for the product in strengths of 5 mg, 10 mg, 15 mg and 25 mg, Cipla said in a regulatory filing. Cipla's Lenalidomide capsules are therapeutic equivalent generic version of Bristol Myers Squibb's Revlimid (Lenalidomide) capsules. Lenalidomide is an immunomodulatory prescription drug indicated for several hematological malignancies in adults such as multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma. Depending on the type of cancer, it can be used as monotherapy or combination as a part of first line regimen, maintenance regimen or relapsed settings, (IMS Health), Revlimid capsules had sales of around USD 2.58 billion in the US for the 12-month period ended June 2022. The product will be available for shipping soon

Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!